Tepkinly access guide: country options for cross-border named-patient access

Editorial and clinical review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.

About Tepkinly

Tepkinly (epcoritamab-bysp) is a CD20-directed CD3 T-cell engaging bispecific antibody approved by the US Food and Drug Administration for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma after two or more lines of systemic therapy in adults (the brand name Tepkinly is used in select international markets; in the United States the product is marketed as Epkinly). The current FDA label is available at accessdata.fda.gov. Tepkinly is marketed by AbbVie and Genmab. Reserve Meds coordinates US-sourced cross-border access to Tepkinly under the named-patient and personal-import framework that governs reference-authority-approved medicines in the patient jurisdiction, with chain-of-custody documentation under the US Drug Supply Chain Security Act (DSCSA). The country-specific access guides listed below set out the regulatory pathway, the tertiary referral context, the documentation bundle the treating physician of record submits to the regulator, and the how to request a written quote for Tepkinly in each jurisdiction Reserve Meds has authored.

Tepkinly country-specific access guides

Reserve Meds has published 14 country-specific access guides for Tepkinly. Each guide covers the regulatory pathway, the tertiary referral context, the documentation package, how quotes work, and the operational sequence Reserve Meds coordinates for that jurisdiction.

Other countries

Reserve Meds has authored country-specific access guides for Tepkinly in the 14 jurisdictions listed above. If your country is not on this list, a lawful pathway may still be available. The Reserve Meds case team will scope your case under the same named-patient or personal-import framework that governs the published guides.

Request a Tepkinly access scope for your country

Related Reserve Meds resources

• Access pathways index (named-patient, personal-import, hospital-exemption, and equivalent frameworks by country)
• Conditions index (the indication families Reserve Meds coordinates around)
• Drug catalog (all FDA-labeled medicines in the Reserve Meds coordination scope)
• All country-specific access guides
• How Reserve Meds coordinates a cross-border case
• Trust, compliance, and editorial review

Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating physician.

Editorial review: Reserve Meds clinical and regulatory team. Last reviewed 2026-06-04.